A model‐based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials
- 18 July 2005
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 25 (12), 2027-2042
- https://doi.org/10.1002/sim.2334
Abstract
The primary aim of a phase I cancer clinical trial is to determine the maximum tolerated dose (MTD) of a new agent. The MTD is determined as the highest dose level of a potential therapeutic agent at which the patients have experienced an acceptable level of dose limiting toxicity. Although many other types of designs have been proposed in recent years, the traditional algorithm-based designs, especially the 3+3 designs, are still widely used due to their practical simplicity. Simulation studies have shown that the traditional algorithm-based designs cannot provide reasonable estimates of the MTD due to their intrinsic design limitations. In this paper, we propose a model-based approach in the estimation of the MTD following a traditional 3+3 design. Simulation results indicate that our model-based approach produces much less biased estimates of the MTD compared to the estimates obtained from the traditional 3+3 designs. Furthermore, our model-based approach can be easily extended to any traditional A+B design. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- Estimating the probability of toxicity at the target dose following an up‐and‐down designStatistics in Medicine, 2003
- Competing designs for phase I clinical trials: a reviewStatistics in Medicine, 2002
- The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial DesignDrug Information Journal, 2001
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trialsBiostatistics, 2001
- Cancer phase I clinical trials: efficient dose escalation with overdose controlStatistics in Medicine, 1998
- BAYESIAN DECISION PROCEDURES FOR DOSE DETERMINING EXPERIMENTSStatistics in Medicine, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- Methods for dose finding studies in cancer clinical trials: A review and results of a monte carlo studyStatistics in Medicine, 1991